Bristol/Agios AML Drug Idhifa Fails In Phase III

IDHENTIFY Studied The IDH2 Inhibitor In Its Approved Indication

microscope
Idhifa missed the overall survival endpoint in Phase III

More from Clinical Trials

More from R&D